Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction

PHASE3CompletedINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2010

Study Completion Date

March 31, 2011

Conditions
Knee Injuries
Interventions
DRUG

OMS103HP

Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours

DRUG

Vehicle

Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours

Trial Locations (18)

16602

University Orthopedics Center - Altoona, Altoona

16801

University Orthopedics Center, State College

23708

Naval Medical Center - Portsmouth, Portsmouth

32611

University of Florida, Gainesville

48073

William Beaumont Hospital, Royal Oak

55454

Minnesota Sports Medicine, Minneapolis

78217

Unlimited Research, San Antonio

78666

Hill Country Sports Medicine, San Marcos

78681

Round Rock Orthopedics, Round Rock

78759

Texas Orthopedics, Austin

79761

Basin Orthopedic Surgical Specialists, Odessa

80110

Colorado Orthopedic Consultants, PC, Englewood

80230

Advanced Orthopedic and Sports Medicine Specialists, Denver

92024

CORE Orthopaedic Medical Center, Encinitas

98431

Madigan Army Medical Center, Tacoma

T2G 5B6

Lifemark Health Research Group, Calgary

L1S 2J5

Rouge Valley Health Systems, Ajax

N6A 3K7

Fowler Kennedy Sport Medicine Clinic, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Omeros Corporation

INDUSTRY

NCT00226772 - Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction | Biotech Hunter | Biotech Hunter